Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AHMED ZAKARI

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1447268297
CMS profile
337556
Location
ALTAMONTE SPRINGS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$78,461.17

105 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AHMED ZAKARI

NPI 1447268297 · CMS profile ID 337556

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology

ALTAMONTE SPRINGS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447268297?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AHMED ZAKARI, NPI 1447268297, CMS profile ID 337556. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447268297?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). AHMED ZAKARI, NPI 1447268297, CMS profile ID 337556. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447268297?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
AHMED ZAKARI, NPI 1447268297, CMS profile ID 337556, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1447268297?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

105 matching records · $78,461.17 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 105 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 105.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Exelixis Inc. $230.0007/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138554350 CMS
Exelixis Inc. $337.8707/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138554352 CMS
Exelixis Inc. $70.0007/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138554354 CMS
Exelixis Inc. $65.0007/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138554356 CMS
Exelixis Inc. $115.0007/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138554358 CMS
Exelixis Inc. $175.0007/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138554348 CMS
Incyte Corporation $3,300.0007/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141210113 CMS
Incyte Corporation $1,650.0006/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141191495 CMS
Incyte Corporation $124.9706/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141191541 CMS
Incyte Corporation $32.8306/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141248672 CMS
AstraZeneca Pharmaceuticals LP $4,450.0005/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104666571 CMS
Incyte Corporation $4,950.0005/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141272106 CMS
AstraZeneca Pharmaceuticals LP $168.0005/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104241531 CMS
AstraZeneca Pharmaceuticals LP $124.5105/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104258135 CMS
AstraZeneca Pharmaceuticals LP $310.7405/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105692827 CMS
Incyte Corporation $3,300.0005/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141267359 CMS
Incyte Corporation $24.9905/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141168501 CMS
Incyte Corporation $59.9905/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141168529 CMS
Incyte Corporation $24.9905/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141168779 CMS
Incyte Corporation $59.9905/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141170091 CMS
Incyte Corporation $342.8405/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141267095 CMS
Incyte Corporation $157.0205/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141267099 CMS
Incyte Corporation $42.8805/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141267101 CMS
Incyte Corporation $426.2005/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141272916 CMS
Incyte Corporation $208.0005/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141191259 CMS
Incyte Corporation $139.9905/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141192557 CMS
E.R. Squibb & Sons, L.L.C. $1,482.0005/14/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101238104 CMS
Incyte Corporation $37.5205/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141173093 CMS
Incyte Corporation $130.0005/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141205323 CMS
Janssen Biotech, Inc. $14.7705/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078396662 CMS
Genentech USA, Inc. $19.7505/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132972849 CMS
AstraZeneca Pharmaceuticals LP $600.0005/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105732921 CMS
Janssen Biotech, Inc. $30.3905/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078396574 CMS
AstraZeneca Pharmaceuticals LP $1,100.0005/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105631635 CMS
Incyte Corporation $275.0005/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141287032 CMS
Daiichi Sankyo Inc. $139.4704/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089501356 CMS
Tempus AI, Inc $14.8604/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150177683 CMS
Janssen Biotech, Inc. $19.3404/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078396673 CMS
Incyte Corporation $87.9903/19/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141267245 CMS
Incyte Corporation $3,300.0003/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141271214 CMS
AstraZeneca Pharmaceuticals LP $3,350.0003/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105381072 CMS
Incyte Corporation $42.8803/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141248820 CMS
Incyte Corporation $99.6603/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141271210 CMS
AstraZeneca Pharmaceuticals LP $111.4802/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104473200 CMS
AstraZeneca Pharmaceuticals LP $41.5402/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104610910 CMS
Novartis Pharmaceuticals Corporation $3,525.0002/21/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087434258 CMS
Novartis Pharmaceuticals Corporation $42.8802/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087434260 CMS
Novartis Pharmaceuticals Corporation $38.3402/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087434262 CMS
TAIHO ONCOLOGY, INC. $113.9002/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137935843 CMS
TAIHO ONCOLOGY, INC. $124.4602/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137940436 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $31,854.37 53
PY2020 $18,867.22 26
PY2021 $22,330.34 31
PY2022 $53,097.07 65
PY2023 $73,881.01 97
PY2024 $78,461.17 105
PY2025 $104,691.06 103

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $181,017.90 37
PY2024 Principal investigator $238,564.92 28
PY2023 Principal investigator $25,743.58 5
PY2022 Principal investigator $26,854.63 4
PY2021 Principal investigator $117,507.63 5
PY2020 Principal investigator $168,310.16 16
PY2019 Recipient $3,752.00 1
PY2019 Principal investigator $162,030.24 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

37 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $1,644.66 12/31/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib E7080,MK-7902 in Combination with Pembrolizumab MK-3475 Versus Lenvatinib in First-line Therapy of Participants with No dispute reported 06/30/2026 1232936502
Principal investigator 1 ABBVIE INC. $642.60 12/23/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403941
Principal investigator 1 ABBVIE INC. $6,119.28 12/04/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403909
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,354.72 11/05/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233734810
Principal investigator 1 ABBVIE INC. $4,445.28 11/04/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403845
Principal investigator 1 ABBVIE INC. $642.40 10/30/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403828
Principal investigator 1 ABBVIE INC. $4,509.00 10/09/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403807
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 10/08/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233734804
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $600.00 10/08/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233734806
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,200.00 10/08/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233734808
Principal investigator 1 ABBVIE INC. $1,200.00 10/01/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403785
Principal investigator 1 ABBVIE INC. $4,445.28 09/03/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403743
Principal investigator 1 ABBVIE INC. $642.60 08/28/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403721
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $950.00 08/15/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233734802
Principal investigator 1 ABBVIE INC. $4,509.00 08/05/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403690
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,709.45 08/01/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233734798
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 08/01/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233734800
Principal investigator 1 ABBVIE INC. $642.60 07/31/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403663
Principal investigator 1 ABBVIE INC. $642.60 07/02/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403604
Principal investigator 1 ABBVIE INC. $8,954.28 07/02/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403613
Principal investigator 1 ABBVIE INC. $351.00 06/18/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403588
Principal investigator 1 ABBVIE INC. $254.88 06/12/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403579
Principal investigator 1 ABBVIE INC. $1,842.60 06/05/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403545
Principal investigator 1 ABBVIE INC. $4,445.28 06/03/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403514
Principal investigator 1 ABBVIE INC. $8,890.56 05/06/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403478
Principal investigator 1 ABBVIE INC. $642.60 05/01/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403467
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,970.00 04/23/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase III,Randomized,Double Blind,Placebo Controlled,Multicenter,Global Study of Rilvegostomig in Combination with Chemotherapy as Adjuvant Treatment in Adult Participants After Resection of Biliary Tract Cancer with Curative Intent Artemide Biliary01 No dispute reported 06/30/2026 1185537393
Principal investigator 1 Genentech, Inc. $1,200.00 04/14/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211539654
Principal investigator 1 ABBVIE INC. $4,445.28 04/03/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403439
Principal investigator 1 ABBVIE INC. $642.60 04/02/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403423
Principal investigator 1 ABBVIE INC. $11,994.75 03/27/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
M24-147 - Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403403
Principal investigator 1 ABBVIE INC. $9,276.12 03/07/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
M24-147 - Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403393
Principal investigator 1 ABBVIE INC. $642.60 03/04/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
M24-147 - Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403378
Principal investigator 1 ABBVIE INC. $4,445.28 02/06/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
M24-147 - Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403347
Principal investigator 1 ABBVIE INC. $642.60 01/29/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
M24-147 - Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403329
Principal investigator 1 AstraZeneca Pharmaceuticals LP $58,532.72 01/06/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
phase II single arm study of durvalumab and bevacizumab following transarterial radioembolization using yttrium 90 glass microspheres therasphere in unresectable hepatocellular carcinoma amenable to locoregional therapy No dispute reported 06/30/2026 1185537395
Principal investigator 1 ABBVIE INC. $4,445.28 01/02/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
M24-147 - Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma No dispute reported 06/30/2026 1202403321